SPL-707 is the first selective and orally bioavailable SPPL2a inhibitor. It shows adequate selectivity against the closely related enzymes γ-secretase and SPP and a good pharmacokinetic profile in mouse and rat. References: Velcicky J, Bodendorf U, Rigollier P, Epple R, Beisner DR, Guerini D, Smith P, Liu B, Feifel R, Wipfli P, Aichholz R, Couttet P, Dix I, Widmer T, Wen B, Brandl T. Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. J Med Chem. 2018 Jan 23. doi: 10.1021/acs.jmedchem.7b01371. [Epub ahead of print] PubMed PMID: 29359565.

纯度：≥98%

CAS：2195361-33-0